Artesunate pessary

Phase 2Small molecule

UUNC Lineberger Comprehensive Cancer Center

Artesunate pessary is one of 41 small molecule programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentActive, not recruiting

TreatmentPhase 2

Active, not recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Alfenta

Jazz Pharmaceuticals

Preclinical

1 2

Niclocide

Bayer

Preclinical

1 3

Theo-Dur

Pfizer

Preclinical

1 4

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 5

Lamprene

Novartis

Preclinical

1 6

Emtriva

Gilead

Preclinical

1 7

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 8

Foscavir

CClinigen, Inc.

Preclinical

6 9

Clomid

Ferring

Preclinical

1 10

Aurlumyn

BBTG International Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT06519994·120 enrolled

Cancer1 trial

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06165614·17 enrolled

Women1 trial

Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06263582·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Artesunate pessary. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Artesunate pessary compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Artesunate pessary. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUNC Lineberger Comprehensive Cancer Center

Artesunate pessary

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Cancer1 trial

Women1 trial

References

Drug Info

Quick Facts

Related News